Trial site

Baotou Central Hospital

Baotou, Inner Mongolia 014040, ChinaNot linked to an institution yet

16running trials
10closed trials

The trials here

What the 26 trials at this site are about, from their registry records.

Conditions: Stroke8 trials
Alzheimer disease4 trials
Asthma2 trials
Chronic rhinosinusitis with nasal polyps2 trials
Mild cognitive impairment2 trials
Type 2 diabetes2 trials
Atopic dermatitis (eczema)1 trial
COPD1 trial
Coronary artery disease1 trial
Heart failure1 trial
Hepatitis B1 trial
High blood pressure1 trial
and 5 more
Phase: Phase 314 trials
Phase 23 trials
Phase 42 trials
Status: Completed10 trials
Recruiting8 trials
Not yet recruiting5 trials
Active, not recruiting3 trials
Lead sponsor: Beijing Tiantan Hospital4 trials
Boehringer Ingelheim2 trials
Capital Medical University2 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.2 trials
and 14 more

Running trials

Not yet recruiting
Drug-Coated Balloon vs Aggressive Medical Management for High-Risk Symptomatic Intracranial Atherosclerotic Stenosis
NCT07830277· Beijing Tiantan Hospital· Source
Contact: Changchun Jiang, MD
Not yet recruiting
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
NCT07466251· Phase 4· Peking Union Medical College Hospital· Source
Contact: Weihai Xu, MD
Recruiting
Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)
NCT07262645· Phase 3· Danyang Huichuang Medical Equipment Co., Ltd.· Source
Contact: Furu Liang, MD, PhD
Active, not recruiting
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
NCT07220538· Phase 4· Dr. Willmar Schwabe GmbH & Co. KG· Source
Not yet recruiting
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Yong Yang, Master
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Jing Wang
Recruiting
Cerebral Large Vessel Occlusion Stroke Multiomics Biosample Cohort
NCT06963489· First Affiliated Hospital of Wannan Medical College· Source
Contact: Xiwa Feng, MD; PhD
Recruiting
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
NCT06829784· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Xiaoyue Chang, Master
Active, not recruiting
Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke
NCT06360458· Phase 3· Wan-Jin Chen· Source
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
China HeadAche DIsorders RegiStry
NCT05334927· Beijing Tiantan Hospital· Source
Contact: Yong Gang Wang, Doctor
Recruiting
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
NCT04948749· Beijing Tiantan Hospital· Source
Contact: Changchun Jiang
Active, not recruiting
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455· Phase 3· Eisai Inc.· Source
Recruiting
The Chinese Familial Alzheimer's Network
NCT03657732· Capital Medical University· Source
Contact: Furu Liang, Doctor
Recruiting
China Cognition and Aging Study
NCT03653156· Capital Medical University· Source
Contact: Furu Liang, Doctor

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Stroke4 recruiting
Alzheimer disease3 recruiting
Asthma1 recruiting
COPD1 recruiting
Heart failure1 recruiting
Hepatitis B1 recruiting
High blood pressure1 recruiting
Liver and biliary tract cancer1 recruiting
Migraine1 recruiting
Mild cognitive impairment1 recruiting
Type 2 diabetes1 recruiting
Vascular dementia1 recruiting

Closed trials

Completed
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
NCT06552520· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Completed
Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps
NCT06439381· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Completed
Budesonide/Formoterol Inhalation Powder in Adults With Asthma
NCT07790159· Phase 3· Shanghai Xin Huanghe Pharmaceutical Co., Ltd.· Source
Completed
A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.
NCT06089278· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Completed
A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis
NCT05975268· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Completed
A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
NCT05881837· Phase 2· Fujian Shengdi Pharmaceutical Co., Ltd.· Source
Completed
Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke
NCT05836740· Phase 3· Beijing Tiantan Hospital· Source
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
NCT05691712· Phase 3· Eli Lilly and Company· Source
Completed
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
NCT05700591· Phase 3· Tasly Biopharmaceuticals Co., Ltd.· Source

Site data: ClinicalTrials.govUpdated 15 Nov 2026

Report an error